CN105624159B - 一种针对人EDIL3基因的siRNA及其应用 - Google Patents
一种针对人EDIL3基因的siRNA及其应用 Download PDFInfo
- Publication number
- CN105624159B CN105624159B CN201610096846.9A CN201610096846A CN105624159B CN 105624159 B CN105624159 B CN 105624159B CN 201610096846 A CN201610096846 A CN 201610096846A CN 105624159 B CN105624159 B CN 105624159B
- Authority
- CN
- China
- Prior art keywords
- edil3
- cell
- gene
- interference sequence
- sirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150076049 EDIL3 gene Proteins 0.000 title abstract description 11
- 108020004459 Small interfering RNA Proteins 0.000 title description 22
- 102100032449 EGF-like repeat and discoidin I-like domain-containing protein 3 Human genes 0.000 claims abstract description 43
- 101001016381 Homo sapiens EGF-like repeat and discoidin I-like domain-containing protein 3 Proteins 0.000 claims abstract description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 230000005764 inhibitory process Effects 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 210000003556 vascular endothelial cell Anatomy 0.000 claims abstract description 10
- 230000035755 proliferation Effects 0.000 claims abstract description 9
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 7
- 230000005012 migration Effects 0.000 claims abstract description 4
- 238000013508 migration Methods 0.000 claims abstract description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 22
- 230000014509 gene expression Effects 0.000 abstract description 18
- 210000003606 umbilical vein Anatomy 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 5
- 230000022131 cell cycle Effects 0.000 abstract description 2
- 231100001231 less toxic Toxicity 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 26
- 238000000034 method Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 210000001542 lens epithelial cell Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 101100170173 Caenorhabditis elegans del-1 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710166164 EGF-like repeat and discoidin I-like domain-containing protein 3 Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610096846.9A CN105624159B (zh) | 2016-02-22 | 2016-02-22 | 一种针对人EDIL3基因的siRNA及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610096846.9A CN105624159B (zh) | 2016-02-22 | 2016-02-22 | 一种针对人EDIL3基因的siRNA及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105624159A CN105624159A (zh) | 2016-06-01 |
CN105624159B true CN105624159B (zh) | 2019-02-05 |
Family
ID=56039504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610096846.9A Active CN105624159B (zh) | 2016-02-22 | 2016-02-22 | 一种针对人EDIL3基因的siRNA及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105624159B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA44908A (fr) * | 2015-09-08 | 2018-07-18 | Sylentis Sau | Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp |
CN114288386B (zh) * | 2022-01-25 | 2023-12-12 | 华中科技大学同济医学院附属协和医院 | Del-1作为炎症性肠病新的生物标志物及治疗药物应用 |
-
2016
- 2016-02-22 CN CN201610096846.9A patent/CN105624159B/zh active Active
Non-Patent Citations (3)
Title |
---|
"NM_005711.4";Kanczkowski W et al.;《GenBank》;20150315;第1页 |
High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients;Jian-Cong Sun et al.;《World Journal of Gastroenterology》;20100928;第16卷(第36期);第4611-4615页 |
Identification of EDIL3 on Extracellular vesicles involved in breast cancer cell invasion;Jeong-Eun Lee et al.;《Journal of Proteomics》;20151014;第131卷;摘要,第19页右栏第5段,第27页右栏第2段,图3 |
Also Published As
Publication number | Publication date |
---|---|
CN105624159A (zh) | 2016-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhu et al. | LINC00052 upregulates EPB41L3 to inhibit migration and invasion of hepatocellular carcinoma by binding miR-452-5p | |
Yang et al. | Downregulation of PDK4 increases lipogenesis and associates with poor prognosis in hepatocellular carcinoma | |
CN106995858A (zh) | 一种与肝癌诊疗相关的lncRNA | |
CN110384800A (zh) | LncRNA XLOC_075168在制备促进血管新生的药物中的应用 | |
Huo et al. | Downregulated lncRNA-MIAT confers protection against erectile dysfunction by downregulating lipoprotein lipase via activation of miR-328a-5p in diabetic rats | |
CN105624159B (zh) | 一种针对人EDIL3基因的siRNA及其应用 | |
Li et al. | LncRNA HCP5 enhances the proliferation and migration of cervical cancer via miR-216a-5p/CDC42 axis | |
Cao et al. | MiR-181 enhances proliferative and migratory potentials of retinal endothelial cells in diabetic retinopathy by targeting KLF6 | |
CN107446927A (zh) | 激活脑胶质瘤u251细胞中lrig1表达的小分子rna、筛选方法及其应用 | |
Arrigoni et al. | Differential angiogenesis of bone and muscle endothelium in aging and inflammatory processes | |
CN107267616A (zh) | 一种非编码基因生物标记物在肝癌中的应用 | |
Li et al. | Hydroxyacid Oxidase 2 (HAO2) Inhibits the Tumorigenicity of Hepatocellular Carcinoma and Is Negatively Regulated by miR‐615‐5p | |
CN107164554A (zh) | Asprv1作为生物标志物在喉鳞癌诊疗中的应用 | |
Cai et al. | Long noncoding RNA XIST regulates cardiomyocyte apoptosis by targeting miR-873-5p/MCL1 axis. | |
CN104328122A (zh) | 一种针对人膜联蛋白A2受体基因的siRNA及其应用 | |
CN106148337A (zh) | 长非编码rna ay927503及其用途 | |
CN105233290B (zh) | C22orf26基因及其表达产物在制备帕金森诊疗试剂中的应用 | |
CN106102772A (zh) | 用于预防和/或治疗与dennd1a变体2相关疾病的组合物和方法 | |
CN101948859B (zh) | 特异性抑制SET蛋白表达的shRNA表达载体及其构建方法和应用 | |
CN105505936B (zh) | 一种抗骨肉瘤转移生物制剂及其应用 | |
CN104267188B (zh) | 针对msk1基因的相关制剂在制备5-fu耐药性检测试剂及5-fu耐药逆转剂方面的应用 | |
CN107227362A (zh) | 一种与肝癌相关的基因及其应用 | |
Shuai et al. | Angiogenic effect of endothelial progenitor cells transfected with telomerase reverse transcriptase on peritubular microvessel in five out of six subtotal nephrectomy rats | |
CN108410975A (zh) | 盆腔脱垂诊断标志物及其应用 | |
CN107881240A (zh) | 骨肉瘤的诊治标志物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Shen Wei Inventor after: Zhong Ming Inventor after: Qin Haifeng Inventor after: Wu Jinhui Inventor after: Xu Qingqiang Inventor after: Song Hongyuan Inventor after: Zhang Rui Inventor before: Shen Wei Inventor before: Zhong Ming Inventor before: Qin Haifeng Inventor before: Wu Jinhui Inventor before: Xu Qingqiang Inventor before: Song Hongyuan Inventor before: Zhang Rui |